Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

HRT tablets highest VTE risk

Thursday January 10th, 2019

Women who take hormone replacement therapy in tablet form may face an increased risk of venous thromboembolism, according to a large UK study published today.

Researchers at Nottingham University say their findings highlight the risks associated with different delivery methods. They found increased risk from HRT delivered by patches, gels or creams.

GP leaders said the findings did not prove that tablets caused an increased risk – only a link.

The study, reported by The BMJ, involved an analysis of the records of more than 2,000 GP practices over a period of 18 years.

The research spanned a time of major changes in prescribing practices as a result of evidence about the risks of HRT that emerged at the beginning of the century.

The researchers found that women taking tablets had twice the risk of suffering VTE compared with those taking other forms of treatment. This is equivalent to nine extra cases among 10,000 women annually.

The researchers say that 80% of HRT treatments continue to be given in tablet form.

There was also a difference in risk between different kinds of tablets. There was a 15% greater risk from HRT derived from horses compared with synthetic oestradiol.

The study compared more than 80,000 women who developed VTE with another 390,000 women who did not.

Researcher Dr Yana Vinogradova, of Nottingham University medical school, said: "Our study has shown that, for oral treatments, different tablets are associated with different risks of developing blood clots, depending on the active components. It has also confirmed that risks of thrombosis for patients using HRT treatments other than tablets (patches or gels) is very low.

“This lower risk has been known for more than ten years and - although patches or gels may not be acceptable in some circumstances - it was surprising to find that only 20% of HRT prescriptions to date have been for non-oral treatments. Our findings are particularly important information for women, who require HRT treatment and are already at increased risk of developing blood clots."

The UK Royal College of GPs said patients should not panic.

Chair Professor Helen Stokes-Lampard said: “While this study is certainly interesting and important, as the authors themselves acknowledge, the findings do not prove that tablets cause more DVTs than patches, just that there is an association. As such, it is essential that more research is conducted in this area, and taken into account, as new clinical guidelines are updated and developed.

“Prescribing is a core skill for GPs and current best practice is to prescribe the lowest possible dose of HRT for the shortest possible time, and so specific products and formulations of HRT are only initiated after a comprehensive discussion between the GP and their patient - and are tailored to meet the best interests of that individual.”

Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 10 January 2019

Tags: Heart Health | Pharmaceuticals | UK News | Women's Health & Gynaecology

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)